Verdiva Bio, a developer of obesity therapies, has launched as a clinical-stage biopharmaceutical company focused on creating innovative therapies for obesity and other cardiometabolic disorders. The company raised $411 million in an oversubscribed Series A financing round, co-led by Forbion and General Atlantic, with additional backing from RA Capital Management, OrbiMed, and others. Verdiva plans to advance a portfolio of next-generation treatments, including first-in-class and best-in-class oral and injectable options. CEO Khurem Farooq emphasized the company’s goal to offer better treatment options for individuals with obesity and related conditions, focusing on improved efficacy, tolerability, and patient access.
Verdiva’s lead programs include a phase 2-ready, once-weekly oral GLP-1 receptor agonist, an oral amylin agonist, and a long-acting subcutaneous amylin agonist, all targeting improved weight management and metabolic health. The company also plans to develop combination therapies. Mohamed Eid, the company’s Chief Medical Officer, highlighted the potential of these therapies to improve adherence and provide sustainable weight loss solutions. The Series A funding will support the clinical development of these assets and expand Verdiva's cardiometabolic portfolio.
